English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Administration of supplementary dose of oral polio vaccine (OPV) during neonatal period is recommended by WHO in countries like India, where host response to the regular to the regular three-dose schedule is not satisfactory and poliomyelitis continues to be a problem. The efficacy of this dose +3, and +5 doses of OPV in terms of seropositivity, seroconversion, systemic, and mucosal antibody responses were measured in 51 infants in a follow-up study from birth to 30 weeks. Administration of the additional dose in the newborn period significantly improved seropositivity and seroconversion rates compared to the conventional 3 or 5 dose schedules. Systemic antibody titres improved with each dose of the vaccine and 40-60 per cent of infants had &gt; 1:128 titres to the three types of polioviruses that could prevent re-infection of the gut and 50 per cent of them had mucosal antibodies as evidenced by specific IgA in nasopharyngeal secretions. Therefore, administration of OPV in the neonatal period should be made compulsory in countries where poliomyelitis still continues to be a problem.

Systemic and mucosal immune response to polio vaccination with additional dose in newborn period